Company Watch

Hepatoprotective nimesulide awaits patent rights

Our News Bureau - Mumbai

Ahmedabad based Lincoln Pharmaceuticals has launched hepatoproctive Nimesulide with the brand name of Namsafe. Nimesulide is well accepted in NSAID and by the medical fraternity. Nimesulide is a very potent anti-inflammatory and anti-pyretic which has captured 20 percent market share in the NSAID segment. Almost all NSAIDs or pain killers due to their metabolic profile, have a complication on the liver. Being a Nimesulide, it has some hepatotoxicity, which is identified by the medical profession. Lincoln Pharmaceuticals is an innovation company and has introduced a new formulation of Nimesulide with Racemethionine to reduce the toxicity of Nimesulide on the liver. The company has conducted four-multi centre clinical trial at various centres under the supervision of well known and renowned orthopaedic surgeons and rheumatologists. One of the clinical trials has recently been conducted at Mumbai by well-known orthopeadic surgeon Dr Prabhu. According to a press note from the company, the investigator has written in conclusion that the liver function test is normal with Namsafe. Other clinical trials have also shown the same performance due to its innovative formulation. Namsafe is now awaiting patent rights.